Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy

MENTOR study Investigators; Paul Brenchley

doi:10.2215/CJN.16631020

Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy

MENTOR study Investigators, Paul Brenchley

Division of Cardiovascular Sciences (L5)

Research output: Contribution to journal › Letter › peer-review

50 Downloads (Pure)

Original language	English
Pages (from-to)	939-941
Number of pages	3
Journal	Clinical journal of the American Society of Nephrology : CJASN
Volume	16
Issue number	6
DOIs	https://doi.org/10.2215/CJN.16631020
Publication status	Published - 11 Jun 2021

Access to Document

10.2215/CJN.16631020

939.fullFinal published version, 176 KB

Cite this

@article{e8352991565f4bf4a3e2f6463ec71152,

title = "Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy",

author = "{MENTOR study Investigators} and Amit Sethi and Jing Miao and Willrich, {Maria Alice V} and Frinack, {Jody L} and Cattran, {Daniel C} and Fervenza, {Fernando C} and Paul Brenchley",

note = "Funding Information: The Membranous Nephropathy Trial of Rituximab (MENTOR) was supported by the Fulk Family Foundation and Genentech Inc. Funding Information: The study was funded by the Mayo Nephrology Collaborative Group – Mayo Clinic Foundation and the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.",

year = "2021",

month = jun,

day = "11",

doi = "10.2215/CJN.16631020",

language = "English",

volume = "16",

pages = "939--941",

journal = "Clinical journal of the American Society of Nephrology : CJASN",

issn = "1555-9041",

publisher = "American Society of Nephrology",

number = "6",

}

TY - JOUR

T1 - Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy

AU - MENTOR study Investigators

AU - Sethi, Amit

AU - Miao, Jing

AU - Willrich, Maria Alice V

AU - Frinack, Jody L

AU - Cattran, Daniel C

AU - Fervenza, Fernando C

AU - Brenchley, Paul

N1 - Funding Information: The Membranous Nephropathy Trial of Rituximab (MENTOR) was supported by the Fulk Family Foundation and Genentech Inc. Funding Information: The study was funded by the Mayo Nephrology Collaborative Group – Mayo Clinic Foundation and the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

PY - 2021/6/11

Y1 - 2021/6/11

U2 - 10.2215/CJN.16631020

DO - 10.2215/CJN.16631020

M3 - Letter

C2 - 33858828

SN - 1555-9041

VL - 16

SP - 939

EP - 941

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

IS - 6

ER -